department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Prilosec · pharmadog

pharmadog
drugs
Prilosec

drug

patient view →

omeprazole DR

Marketedupdated 2mo ago

by Covis Pharmaceuticals Inc (Inactive)

Approved

community read0 votes

all catalysts(38)

approval · 38

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE — FDA approval

OMEPRAZOLE AND SODIUM BICARBONATE (OMEPRAZOLE) — FDA approval

OMEPRAZOLE — FDA approval

view all 38 catalysts →

News(0)

no news has mentioned this drug yet

brand

Prilosec

generic

omeprazole

indication

Multiple Endocrine Adenomas

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Dec 8, 2036

~10.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Mar 1, 2040method-of-use (U-623)US 11771686
Jul 16, 2039formulationUS 10751333
Jul 16, 2039formulationUS 11103492
Jul 16, 2039formulationUS 11633478
Jul 16, 2039method-of-use (U-624)US 11911473
Jul 16, 2039formulationUS 12042539
Jul 16, 2039formulationUS 12329752
Jul 16, 2039formulationUS 12440566
Dec 8, 2036formulationUS 10076494
Dec 8, 2036formulationUS 10835488

Data sources

openFDA · ClinicalTrials.gov

last refreshed 53m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval110 co-mentions · 54 sources
drugOMEPRAZOLE AND SODIUM BICARBONATE63 co-mentions · 57 sources
drugOMEPRAZOLE63 co-mentions · 57 sources
drugomeprazole XR-ODT63 co-mentions · 57 sources
tagSmall Molecule55 co-mentions · 54 sources
companyDexcel Pharma Ltd27 co-mentions · 27 sources
drug(omeprazole + sodium bicarbonate)16 co-mentions · 16 sources
tagRecall5 co-mentions · 3 sources

Trials studying omeprazole DR

phase1A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancerrecruitingn=136
phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapyactive not recruitingn=420
phase1A Multiple Dose Study of LY3502970 in Healthy Participantscompletedn=26
phase1An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substratescompletedn=23
phase1A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjectscompletedn=40
phase1Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxincompletedn=13
phase1Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participantscompletedn=30
phase1Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)recruitingn=134

more trials →